| |
NewswireTODAY - /newswire/ -
Monrovia, CA, United States, 2009/07/29 - Amy M. Scott-Billman, Vice President of Global Regulatory Strategy for Immunotherapeutics at GlaxoSmithKline Biologicals, to do Keynote Presentation at GTCbio’s 5th Modern Drug Discovery & Development Summit on October 14-16, 2009 in San Diego, CA.
|
| |
|
| |
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements
Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!
|
| |
Amy Scott-Billman, Vice President of Global Regulatory Strategy for Immunotherapeutics at GlaxoSmithKline Biologicals, is to give a keynote presentation concerning regulatory considerations & challenges for immunotherapeutic/diagnostic co-development at GTCbio’s 5th Modern Drug Discovery & Development Summit, on October 14th-16th, 2009, in San Diego, CA.
Amy’s presentation highlights GSK's approach to immunotherapy for cancer (Antigen-Specific Cancer Immunotherapeutics), challenges of co-development - biologic & companion in vitro diagnostics (screening assays & biomarkers), development/regulatory challenges/considerations for the biologic component, and development/regulatory challenges/considerations for the in vitro diagnostic component.
Amy is the Vice President of Global Regulatory Strategy for Immunotherapeutics at GlaxoSmithKline Biologicals (GSK Bio) where she manages a global staff responsible for all regulatory activities relevant to the development and commercialization of immunotherapeutic products for cancer and chronic disorder indications. Amy is also responsible for the regulatory aspects of in-licensing opportunities and for partnerships with external parties for the global development of companion in vitro diagnostics.
Prior to joining regulatory affairs at GSK in 1998, Amy served in GSK’s World Wide Supply Operations as a Director of Quality Assurance & Compliance; supporting various business units including Research & Development, Biopharmaceuticals and Pharmaceuticals. Before joining GSK, Amy served for nearly 9 years at the Center for Biologics Evaluation and Research (CBER) at the US FDA in several capacities, including senior management, reviewer and inspector of biopharmaceutical manufacturing facilities. Amy received her B.S. in Microbiology from Pennsylvania State University and her M.S. in Biotechnology from Johns Hopkins University.
|
| |
 |
| |
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements
Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!
|
| |
Agency / Source: GTCbio - Biopharmaceutical Conference
|
| |
 |
| |
Availability: All Regions (Including Int'l)
|
| |
Traffic Booster: [/] Quick NewswireToday Visibility Checker
|
| |
Distribution / Indexing: [+]
|
| |
 |
| |
# # #
|
| |
|
| |
 |
| |
Your Banner Ad showing on ALL Pharma / BioTech / Nutrition articles, CATCH Visitors via Your Competitors Announcements!
 Company website links NOT available to basic submissions |
|
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source. |
| |
 |
| |
For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
| |
Contact: Josette Barba
626-256-6405 infogtcbio[.]gtcbio.com
|